Kala Bio Inc (KALA) Stock Price, Quote & News

Company Profile

KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The comp...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 996 5252

Fax: 781 642 0399

Website: www.kalarx.com

Address:

1167 Massachusetts Avenue, Arlington, United States

Drive2 Jul. 28 at 11:10 PM

$KALA Investors are asleep on this one. They didn't watch the KOL presentation.

0 · Reply

JazsminC Jul. 28 at 2:51 PM

$KALA Consolidation and some people taking profits if they have been holding since april.

0 · Reply

MythicalDragon Jul. 28 at 2:26 PM

$KALA Looks good for a nice uptrend from here

0 · Reply

Drive2 Jul. 27 at 4:58 PM

$KALA $3B sales estimates once this is approved.

0 · Reply

JoseRodriguez1994 Jul. 27 at 4:44 PM

$KALA Interesting

0 · Reply

Drive2 Jul. 27 at 12:58 PM

$KALA Investors completely asleep on this one. Watch the KOL presentation especially the Q and A.

0 · Reply

yuezhoulin123 Jul. 26 at 3:15 AM

$KALA wow

0 · Reply

Ray_Khan Jul. 26 at 3:05 AM

Week of 7/28/25 List: *Down to 1/4 position $LIDR . I wanna see where this goes. *Holding my remaining 1/4 position in $KALA as well. $7 stop. *Full position $OLB . I generally agree with the bullish DD and I'd be surprised if we don't see at least a 200% move when approval drops. And that's about to happen, in fact, it may already have and they're timing the release for optimal effect. I would. *Not sure what to make of my $TSLA here. I'm still a confirmed Tesla bull long term, but I'm going to pause my weekly adds temporarily and see what happens. I also like bagels with Lox and cream cheese baby. LFG!

1 · Reply

Stmkr Jul. 26 at 2:25 AM

$KALA Base case scenario is KALA needing a ph3 for approval. But if results from current trial are convincing enough I wouldn't rule out an early approval pathway

1 · Reply

Stmkr Jul. 26 at 2:23 AM

$KALA Early phase data pretty impressive. Especially the patienr with PCED for 213 days that resolved within a week of KPI-012 treatment.

0 · Reply

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

May 29, 2025, 8:00 AM EDT - 2 months ago

KALA BIO to Present at Jefferies Global Healthcare Conference

Feb 12, 2025, 8:00 AM EST - 5 months ago

KALA BIO Announces Chief Executive Officer Transition

Dec 30, 2024, 8:00 AM EST - 7 months ago

KALA BIO Announces $10,750,000 Private Placement

Nov 27, 2024, 8:00 AM EST - 8 months ago

KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference

May 14, 2024, 4:05 PM EDT - 1 year ago

KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update

Mar 29, 2024, 8:00 AM EDT - 1 year ago

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Feb 26, 2024, 8:00 AM EST - 1 year ago

KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

Jan 19, 2024, 4:01 PM EST - 1 year ago

KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 13, 2023, 8:00 AM EST - 1 year ago

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Sep 5, 2023, 8:00 AM EDT - 2 years ago

KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference

Aug 4, 2023, 8:00 AM EDT - 2 years ago

KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 2, 2023, 4:01 PM EDT - 2 years ago

KALA BIO to Participate in Upcoming Investor Conferences in August

Jul 19, 2023, 4:01 PM EDT - 2 years ago

Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 2, 2023, 8:00 AM EDT - 2 years ago

Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference

May 9, 2023, 8:00 AM EDT - 2 years ago

Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Apr 28, 2023, 8:00 AM EDT - 2 years ago

Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED

Mar 27, 2023, 8:00 AM EDT - 2 years ago

Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED

Mar 8, 2023, 4:01 PM EST - 2 years ago

Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Mar 3, 2023, 8:00 AM EST - 2 years ago

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Jan 19, 2023, 7:12 AM EST - 2 years ago

Kala Pharma: Rare Eye Disease Biotech Lottery Ticket Based On Stem Cell Platform

Dec 30, 2022, 12:02 PM EST - 2 years ago

Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment

Dec 29, 2022, 8:30 AM EST - 2 years ago

Kala Pharmaceuticals Stock Continues To Soar: What's Going On? - Kala Pharmaceuticals (NASDAQ:KALA)

Dec 28, 2022, 6:48 AM EST - 2 years ago

Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment

Dec 27, 2022, 4:01 PM EST - 2 years ago

Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Nov 28, 2022, 4:02 PM EST - 2 years ago

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

Nov 28, 2022, 4:01 PM EST - 2 years ago

Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing

Nov 8, 2022, 8:00 AM EST - 2 years ago

Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 1, 2022, 7:30 AM EDT - 2 years ago

Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors

Oct 20, 2022, 7:30 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Reverse Stock Split

Sep 6, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

Aug 19, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Aug 18, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

Aug 12, 2022, 7:51 PM EDT - 3 years ago

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q2 2022 Results - Earnings Call Transcript

Aug 11, 2022, 7:00 AM EDT - 3 years ago

Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 4, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Jul 11, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals Completes Sale of EYSUVIS® and INVELTYS® to Alcon Inc

Jun 2, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Present at Jefferies Healthcare Conference

May 23, 2022, 10:17 AM EDT - 3 years ago

Why Kala Pharmaceuticals Shares Are Rising Today

May 23, 2022, 12:01 AM EDT - 3 years ago

Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.

May 16, 2022, 10:54 AM EDT - 3 years ago

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q1 2022 Results - Earnings Call Transcript

May 16, 2022, 7:00 AM EDT - 3 years ago

Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 9, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call

May 2, 2022, 1:25 PM EDT - 3 years ago

Kala Pharmaceuticals Posts KPI-012 Data In Healing Impaired Ocular Diseases

May 1, 2022, 9:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting

Apr 4, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals to Present Phase 1b Clinical Data for KPI-012 in Patients with PCED at 2022 ARVO Annual Meeting

Mar 29, 2022, 12:10 PM EDT - 3 years ago

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q4 2021 Results - Earnings Call Transcript

Mar 29, 2022, 7:00 AM EDT - 3 years ago

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Mar 23, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call

Mar 8, 2022, 4:19 PM EST - 3 years ago

This Microcap Pharma Stock Almost Doubled Today - Read Why

Drive2 Jul. 28 at 11:10 PM

$KALA Investors are asleep on this one. They didn't watch the KOL presentation.

0 · Reply

JazsminC Jul. 28 at 2:51 PM

$KALA Consolidation and some people taking profits if they have been holding since april.

0 · Reply

MythicalDragon Jul. 28 at 2:26 PM

$KALA Looks good for a nice uptrend from here

0 · Reply

Drive2 Jul. 27 at 4:58 PM

$KALA $3B sales estimates once this is approved.

0 · Reply

JoseRodriguez1994 Jul. 27 at 4:44 PM

$KALA Interesting

0 · Reply

Drive2 Jul. 27 at 12:58 PM

$KALA Investors completely asleep on this one. Watch the KOL presentation especially the Q and A.

0 · Reply

yuezhoulin123 Jul. 26 at 3:15 AM

$KALA wow

0 · Reply

Ray_Khan Jul. 26 at 3:05 AM

1 · Reply

Stmkr Jul. 26 at 2:25 AM

$KALA Base case scenario is KALA needing a ph3 for approval. But if results from current trial are convincing enough I wouldn't rule out an early approval pathway

1 · Reply

Stmkr Jul. 26 at 2:23 AM

$KALA Early phase data pretty impressive. Especially the patienr with PCED for 213 days that resolved within a week of KPI-012 treatment.

0 · Reply

Stmkr Jul. 26 at 2:20 AM

$KALA "Oxervate reported US 2023 annual sales exceeded $828M*" Oxervate is approved for only 1/3 of PCED patients and is a complicated regimen (6 times daily + complicated preparation) with topical AEs being common (e.g. pain) KPI-012 aiming for a broad PCED label, QID dosing, is ready to use (no steps to prepare for administration) and is not only painless but on the contrary results in very quick resolution of the pain. Guess what happens to KALA price when positive results are announced late Q3 (current MC around 50M!). Check what happened to KALA when ph1b results were announced

1 · Reply

StockScanners Jul. 25 at 10:43 PM

$KALA needs to hold above 7.85

0 · Reply

Brachina Jul. 25 at 8:45 PM

$KALA nice close. Have a nice weekend

0 · Reply

JazsminC Jul. 25 at 8:07 PM

$KALA Well that was a nice way to end the week

0 · Reply

cfvk Jul. 25 at 7:37 PM

$KALA my 5.6 enjoying, just been flipping it from 5s to 6s but it's getting attention

0 · Reply

JazsminC Jul. 25 at 7:35 PM

$KALA Wow we are movin

0 · Reply

Raxothus Jul. 25 at 4:38 PM

EOD FOLLOW-UP – 07/25/25 Tracking continuation watch from 07/24 based on today’s highs vs prior close ✅ $KALA – Closed 7.10, weak open, hit 7.90 HOD (+11.3%), but never reclaimed VWAP. ✅ $OPTX – Closed 2.28, hit 2.50 HOD (+9.6%), reclaimed VWAP early, strong push. ✅ $ENGS – Closed 3.09, ran to 3.14 HOD (+1.6%), low-range but clean continuation with volume. ❌ $PHOE – Closed 10.73, hit 10.71 (–0.2%), no gap or VWAP reclaim. ❌ $CIO – Closed 6.90, no move, no volume. No trigger. Recap Total: 5 Winners: 3 Faders: 2 Accuracy: 60% ⚠️ $OPTX and $ENGS confirmed with volume. $KALA had range but failed VWAP hold. $PHOE and $CIO offered no valid setup. #VWAP #Continuation #SmallCaps #DayTrading #EODSetups #Accountability

0 · Reply

Nothin Jul. 25 at 4:10 PM

$KALA Top Institutional Holders (As of March/December 2024 filings) 1. Baker Bros. Advisors L.P. • Owns approximately 1,201,894 shares (~19.7% of the company), following a 34.8% increase in their stake during Q4 2024 • Position valued at about $8.34 million 2. Cormorant Asset Management, LP • Holds 609,027 shares, representing 9.99% of outstanding shares • This is a new position reported as of Dec 31, 2024 3. SR One Capital Management, LP • Controls 598,940 shares after boosting their position by 35% during Q4 • Represents around 1% of their portfolio (approx. $4.16M stake) 4. Perceptive Advisors LLC • Holds 277,610 shares, valued at about $1.59M (as of March 31, 2025) Also notable: AIGH Capital Management LLC • Made a new investment of 121,302 shares (~$842K) in Q4 2024 • Not yet at the same scale, but an emerging player

0 · Reply

_ICEMAN Jul. 25 at 4:00 PM

$KALA news coming?

0 · Reply

PLATINUM_TRADES Jul. 25 at 3:20 PM

$KALA $7.89 high thank you for the awesome overnight swing... 49 straight overnight swings without a loss the streak continues🏆🏆

0 · Reply

PLATINUM_TRADES Jul. 25 at 2:15 PM

$KALA $7.50 to break for more.... Still going strong 🚨 🚨

0 · Reply

JazsminC Jul. 25 at 2:10 PM

$KALA Volume is really good almost at average

0 · Reply

Market Cap	52.20M
Revenue (ttm)	0.00
Net Income (ttm)	-38.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	6.18

Volume	208,500
Avg Vol	114,042
Day's Range	N/A - N/A
Shares Out	6.45M
Stochastic %K	82%
Beta	-1.88
Analysts	Strong Sell
Price Target	$13.00